![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 11, 2009 1:05:52 PM
Biography
William A. Carter, M.D.
William A. Carter, M.D., is Chairman, CEO of HEMISPHERx Biopharma, Inc.,
(NASDAQ: HEMX). He is the co-inventor of Ampligen, and is a co-inventor of
record on over 200 patents relating to the Company's technology. Dr. Carter
was a leading innovator in the development of human interferon for a variety
of treatment indications including various viral diseases and cancer. In this
context, he received the first FDA approval to initiate clinical trials on a
beta interferon product manufactured in the U.S. under his supervision.
His interest in CFS/CFIDS goes back to 1987 when he and several board members
became acquainted with PWC's and their severely debilitating disease. He
regularly attends scientific meetings and presentations on research about the
diagnosis and treatment of CFS/CFIDS, most recently the American Association
for Chronic Fatigue Syndrome (AACFS) annual conference in San Francisco on
October 13-16, 1996.
Dr. Carter serves as Professor of Medicine at Allegheny University, PA., a
position he has held since 1980. He is also director of Clinical Research for
the University's Institute for Cancer and Blood Diseases. Dr. Carter has
served as professor at Johns Hopkins School of Medicine, Hahnemann
University, and the State University of New York at Buffalo.
Dr. Carter received his degree from Duke University and underwent his
post-doctoral training at the National Institutes of Health and Johns Hopkins
University. He is currently a consultant to the NIH. He is the author of over
125 published sceintific articles including the Co-Editor, Handbook of
Experimental Pharmacology on Interferon, Springer-Verlag, Publisher. In
addition, Dr. Carter has authored or co-authored nearly 40 book sections.
Contacts:
William A. Carter, CEO, HEMISPHERx Biopharma, Inc. (215) 988-0080
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM